Sugi Predict
/ Targets
/ H1-4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to H1-4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia |
PHASE4 | COMPLETED |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia |
PHASE3 | COMPLETED |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Vorinostat in Children |
PHASE1/PHASE2 | COMPLETED |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma |
PHASE2 | RECRUITING |
| An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab |
PHASE1/PHASE2 | RECRUITING |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis |
PHASE1/PHASE2 | RECRUITING |
| LBH589 Treatment for Refractory Clear Cell Renal Carcinoma |
PHASE2 | COMPLETED |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG |
PHASE1/PHASE2 | RECRUITING |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer |
PHASE2 | COMPLETED |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia |
PHASE2 | UNKNOWN |
| Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma |
PHASE1 | UNKNOWN |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases |
PHASE1 | COMPLETED |
| Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
PHASE1 | COMPLETED |
| CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults |
PHASE1 | RECRUITING |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults |
PHASE1 | COMPLETED |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins |
nan | COMPLETED |
| Impact of Air Quality on the Effectiveness of Standard of Care Therapy in Children With Autism Spectrum Disorder: A Prospective Longitudinal Study |
nan | NOT_YET_RECRUITING |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia |
nan | COMPLETED |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity |
nan | COMPLETED |
| Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a H1-4 binder may also engage these)